Evotec and Odyssey Therapeutics Collaborate on AI-Enabled Drug Discovery

Evotec and Odyssey Therapeutics have formed a collaboration aimed at advancing the discovery of new treatments for autoimmune and inflammatory diseases. This partnership will integrate Odyssey's deep understanding of disease biology with Evotec's artificial intelligence-enabled drug discovery platform.

The collaboration will involve Evotec providing its advanced screening capabilities and proprietary compound libraries. Evotec's role will be to deliver validated hit series for Odyssey's early-stage discovery programs. Financial terms of the agreement were not disclosed.

Odyssey Therapeutics is focused on developing novel therapies for patients suffering from autoimmune and inflammatory conditions. Evotec, a drug discovery and development company, offers a wide range of services and platforms, including AI-driven solutions to identify and validate drug targets and candidates.